Detalhe da pesquisa
1.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
N Engl J Med
; 389(10): 877-888, 2023 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351564
2.
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet
; 402(10400): 472-483, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369232
3.
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial.
Cardiovasc Diabetol
; 22(1): 52, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36899386
4.
A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
Diabetes Obes Metab
; 24(2): 302-311, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34697882
5.
Examining the evidence for weight management in individuals with type 2 diabetes.
Diabetes Obes Metab
; 24(8): 1411-1422, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545861
6.
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
N Engl J Med
; 389(24): 2304-2305, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38091543
7.
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Cardiovasc Diabetol
; 20(1): 194, 2021 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34563178
8.
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
Diabetes Obes Metab
; 23(1): 106-115, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945083
9.
Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
Diabetes Obes Metab
; 23(2): 508-519, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33140575
10.
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
Diabetes Obes Metab
; 23(10): 2279-2288, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159708
11.
Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results.
Diabetes Obes Metab
; 22(12): 2209-2226, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32744372
12.
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.
J Clin Pharmacol
; 64(2): 215-226, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37853524
13.
Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
Diabetes Ther
; 15(4): 855-867, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427164
14.
Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunction.
J Lipid Res
; 54(4): 953-65, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23345411
15.
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
Diabetes Ther
; 13(11-12): 1921-1932, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36131064
16.
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
Diabetes Care
; 45(3): 547-554, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35043140
17.
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
Diabetes Ther
; 12(10): 2783-2794, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514554
18.
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.
Kidney360
; 2(2): 254-262, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373017
19.
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
J Clin Endocrinol Metab
; 106(5): 1345-1351, 2021 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33537745
20.
Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
Diabetes Ther
; 11(7): 1437-1466, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32524494